###begin article-title 0
###xml 88 93 <span type="species:ncbi:10090">mouse</span>
TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus
###end article-title 0
###begin p 1
###xml 27 43 27 43 <email xmlns:xlink="http://www.w3.org/1999/xlink">puilee05@ufl.edu</email>
CORRESPONDENCE Pui Y. Lee: puilee05@ufl.edu
###end p 1
###begin p 2
This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see ). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at ).
###end p 2
###begin p 3
###xml 796 812 796 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arthritis Rheum.</italic>
###xml 1272 1276 1272 1276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR7</italic>
###xml 431 435 <span type="species:ncbi:10090">mice</span>
Increased type I interferon (IFN-I) production and IFN-stimulated gene (ISG) expression are linked to the pathogenesis of systemic lupus erythematosus (SLE). Although the mechanisms responsible for dysregulated IFN-I production in SLE remain unclear, autoantibody-mediated uptake of endogenous nucleic acids is thought to play a role. 2,6,10,14-tetramethylpentadecane (TMPD; also known as pristane) induces a lupus-like disease in mice characterized by immune complex nephritis with autoantibodies to DNA and ribonucleoproteins. We recently reported that TMPD also causes increased ISG expression and that the development of the lupus is completely dependent on IFN-I signaling (Nacionales, D.C., K.M. Kelly-Scumpia, P.Y. Lee, J.S. Weinstein, R. Lyons, E. Sobel, M. Satoh, and W.H. Reeves. 2007. Arthritis Rheum. 56:3770-3783). We show that TMPD elicits IFN-I production, monocyte recruitment, and autoantibody production exclusively through a Toll-like receptor (TLR) 7- and myeloid differentiation factor 88 (MyD88)-dependent pathway. In vitro studies revealed that TMPD augments the effect of TLR7 ligands but does not directly activate TLR7 itself. The effects of TMPD were amplified by the Y-linked autoimmune acceleration cluster, which carries a duplication of the TLR7 gene. In contrast, deficiency of Fcgamma receptors (FcgammaRs) did not affect the production of IFN-I. Collectively, the data demonstrate that TMPD-stimulated IFN-I production requires TLR7/MyD88 signaling and is independent of autoantibody-mediated uptake of ribonucleoproteins by FcgammaRs.
###end p 3
###begin p 4
Abbreviations used: ago2, argonaute 2; ANA, antinuclear antibody; clo-lip, clodronate-containing liposomes; ds, double stranded; IC, immune complex; IFN-I, type I IFN; IPS-1, IFN-b promoter stimulator 1; IRF, IFN regulatory factor; ISG, IFN-stimulated gene; MCP, monocyte chemoattractant protein; Mda5, melanoma differentiation-associated gene 5; MFI, mean fluorescence intensity; Mx1, myxoma response protein 1; MyD88, myeloid differentiation factor 88; PDC, plasmacytoid DC; PEC, peritoneal exudate cell; RIG-I, retinoic acid-inducible gene I; RT-PCR, real-time quantitative PCR; SLE, systemic lupus erythematosus; snRNP, small nuclear ribonucleoprotein; ss, single stranded; TBK-1, TANK-binding kinase 1; TLR, Toll-like receptor; TMPD, 2,6,10,14-tetramethylpentadecane; TRIF, Toll/IL-1 receptor domain-containing adaptor inducing IFN-b; Yaa, Y-linked autoimmune accelerating.
###end p 4
###begin p 5
###xml 349 350 349 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 651 652 651 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 653 654 653 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 803 804 803 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 806 807 806 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 600 608 <span type="species:ncbi:9606">patients</span>
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of antibodies against an array of self-antigens such as double-stranded (ds) DNA and components of small nuclear ribonucleoproteins (snRNPs), including the Sm/RNP antigens (U1, U2, U4-6, and U5 snRNPs), Ro/SS-A antigens (Y RNAs), and other antigens (1). Recent evidence strongly suggests that type I IFNs (IFN-Is), a family of antiviral cytokines, are integral to the pathogenesis of SLE. Elevated serum levels of IFN-I and overexpression of IFN-stimulated genes (ISGs) in the peripheral blood of SLE patients have been demonstrated by several groups (2-4). This "IFN signature" is associated with more active disease and the presence of autoantibodies against dsDNA and the Sm/RNP and Ro/SS-A antigens (5, 6).
###end p 5
###begin p 6
###xml 385 386 382 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 569 570 566 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 571 573 568 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 964 966 958 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 967 969 961 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 1128 1130 1122 1124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 1132 1134 1126 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
The etiology of excess IFN-I in SLE is incompletely understood. Research on innate immunity has led to the identification of several pathways mediating IFN-I production in mammalian cells. Toll-like receptor (TLR) 3, a sensor for viral dsRNA, and TLR4, the receptor for LPS, both stimulate IFN-I secretion through Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) (7). In contrast, TLR7/8 and TLR9 mediate IFN-I production via myeloid differentiation factor 88 (MyD88) in response to single-stranded (ss) RNA and unmethylated CpG DNA, respectively (8-10). In addition, cytoplasmic receptors that recognize intracellular nucleic acids and induce IFN-I have been described recently. Retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated gene 5 (MDA5) recognize cytoplasmic RNA and trigger IFN-I by activating IFN-beta promoter stimulator 1 (IPS-1; also known as MAVS, VISA, and CARDIF) and IFN regulatory factor (IRF) 3 (11-14). Cytoplasmic DNA binds to a newly described cytoplasmic sensor and triggers IFN-I production via a pathway requiring TANK-binding kinase 1 (TBK-1) and IRF3 (15, 16).
###end p 6
###begin p 7
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 455 457 455 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 459 461 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 587 589 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 695 697 691 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 698 700 694 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 607 612 <span type="species:ncbi:10090">mouse</span>
It has been hypothesized that nucleic acids from dying cells may act as ligands for TLR7/8 and TLR9 to trigger IFN-I production in SLE. Immune complexes (ICs) formed by autoantibodies to DNA and snRNPs help to transport these "endogenous ligands" to endosomes where TLR7, 8, and 9 are normally found (17). Activation of these TLRs then induces the production of IFN-I by plasmacytoid DCs (PDCs). This hypothesis is supported by numerous in vitro studies (18, 19). However, therapeutic administration of recombinant IFN-alpha can directly trigger the production of anti-dsDNA antibodies (20), and in several mouse model of lupus, IFN-I production is required for the induction of autoantibodies (21-23), suggesting that IFN-I dysregulation may occur upstream of autoantibody development. Therefore, it remains controversial whether nucleic acid-containing ICs in SLE initiate IFN-I production or act to perpetuate a positive feedback loop of IFN production initiated by another factor, such as a viral infection.
###end p 7
###begin p 8
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 504 507 504 507 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 515 517 515 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 554 556 554 556 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 717 719 717 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 751 753 751 753 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 171 176 <span type="species:ncbi:9606">human</span>
###xml 509 513 <span type="species:ncbi:10090">mice</span>
Experimental lupus induced by the hydrocarbon oil 2,6,10,14-tetramethylpentadecane (TMPD; also known as pristane) displays many key immunological and clinical features of human SLE, including the presence of the IFN signature and lupus autoantibodies such as anti-dsDNA, -Sm, and -RNP (24-26). Importantly, IFN-I play an essential role in this model, as the development of glomerulonephritis and production of autoantibodies (anti-Sm/RNP, -dsDNA, and -Su) are abolished in IFN-I receptor-deficient (IFNAR-/-) mice (22). Unexpectedly, a population of Ly6Chi immature monocytes that accumulates in the peritoneal cavity after TMPD treatment, rather than DCs, is the major source of the excess IFN-I seen in this model (27). The persistent influx of Ly6Chi monocytes and production of IFN-I occur within 2 wk of TMPD treatment, long before the appearance of autoantibodies against snRNPs and dsDNA (3-5 mo), indicating that the initial wave of IFN-I production may be independent of the presence of RNA-containing ICs. In this study, we aimed to elucidate the mechanism of IFN-I production in TMPD-induced lupus.
###end p 8
###begin title 9
RESULTS
###end title 9
###begin title 10
TMPD-induced IFN-I production requires MyD88
###end title 10
###begin p 11
###xml 218 219 218 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 272 273 272 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 274 276 274 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 380 381 380 381 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 385 387 385 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 520 522 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 641 644 641 644 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 672 680 672 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
###xml 692 694 692 694 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 739 740 739 740 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 744 745 744 745 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 749 752 749 752 <sup xmlns:xlink="http://www.w3.org/1999/xlink">mid</sup>
###xml 778 793 778 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, A and B</xref>
###xml 922 947 922 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myxoma response protein 1</italic>
###xml 949 952 949 952 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mx1</italic>
###xml 958 962 958 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IRF7</italic>
###xml 993 996 993 996 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1041 1049 1041 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 1231 1239 1231 1239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 D</xref>
###xml 1359 1370 1359 1370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, A&#8211;D</xref>
###xml 1575 1577 1568 1570 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 1611 1614 1604 1607 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1621 1632 1614 1625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, A&#8211;D</xref>
###xml 1719 1734 1712 1727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, A and B</xref>
###xml 94 98 <span type="species:ncbi:10090">mice</span>
###xml 452 456 <span type="species:ncbi:10090">mice</span>
###xml 549 553 <span type="species:ncbi:10090">mice</span>
###xml 645 649 <span type="species:ncbi:10090">mice</span>
###xml 997 1001 <span type="species:ncbi:10090">mice</span>
###xml 1035 1039 <span type="species:ncbi:10090">mice</span>
###xml 1615 1619 <span type="species:ncbi:10090">mice</span>
To identify the mechanism of IFN-I induction by TMPD, we first analyzed the effect of TMPD on mice with deficiency of the adaptor molecules TRIF or MyD88. TRIF is required to trigger IFN-I production by TLR3 and TLR4 (7), whereas MyD88 mediates TLR7/8 and TLR9 signaling (8-10). We have previously shown that within 2 wk of TMPD treatment, an accumulation of IFN-I-producing CD11b+Ly6Chi monocytes can be detected in the peritoneal cavity in wild-type mice concurrent with increased IFN-I production and ISG expression (27). Compared with wild-type mice, the total number of peritoneal exudate cells (PECs) was significantly reduced in MyD88-/- mice after TMPD treatment (Fig. 1 A). Both Ly6Chi monocytes and granulocytes (defined as CD11b+Ly6G+Ly6Cmid) were decreased by >90% (Fig. 1, A and B). Importantly, we found that IFN-I induction by TMPD was completely dependent on MyD88, because elevated expression of the ISGs myxoma response protein 1 (Mx1) and IRF7 in PECs was abolished in MyD88-/- mice, as also seen in IFNAR-deficient mice (Fig. 1 C). The levels of the IFN-inducible chemokine monocyte chemoattractant protein 1 (MCP-1; also known as CCL2) in the peritoneal lavage fluid were also reduced in the absence of MyD88 (Fig. 1 D). In contrast, TRIF deficiency did not affect the accumulation of PEC populations or the increased expression of ISGs (Fig. 1, A-D). Although we were unable to detect significant changes in serum IFN-alpha/beta levels by ELISA, IFN-I secretion was required for the response to TMPD, as the up-regulation of ISGs and recruitment of Ly6Chi monocytes were abolished in IFNAR-/- mice (Fig. 1, A-D). The absence of IFN-I signaling, however, did not affect the influx of granulocytes (Fig. 1, A and B).
###end p 11
###begin p 12
###xml 0 45 0 45 <bold xmlns:xlink="http://www.w3.org/1999/xlink">TMPD-induced IFN-I production requires MyD88.</bold>
###xml 94 96 94 96 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 165 166 165 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 178 181 178 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 183 184 183 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 195 198 195 198 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 200 201 200 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 217 220 217 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 227 228 227 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 293 295 293 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 370 373 370 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mx1</italic>
###xml 378 382 378 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IRF7</italic>
###xml 694 695 694 695 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 866 867 866 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 221 225 <span type="species:ncbi:10090">mice</span>
###xml 462 467 <span type="species:ncbi:10090">mouse</span>
###xml 551 555 <span type="species:ncbi:10090">mice</span>
TMPD-induced IFN-I production requires MyD88. (A) Comparison of the number of total PECs, Ly6Chi monocytes, and granulocytes 2 wk after TMPD treatment in wild-type (n = 5), MyD88-/- (n = 6), TRIF-/- (n = 4), and IFNAR-/- mice (n = 4). (B) Flow cytometry of peritoneal cells (box indicates Ly6Chi monocytes and dashed oval indicates granulocytes). (C) RT-PCR analysis of Mx1 and IRF7 expression in PECs (normalized to peritoneal cells from an untreated wild-type mouse). (D) ELISA quantification of MCP-1 in the peritoneal lavage fluid of TMPD-treated mice. (E) Flow cytometry analysis of Sca-1 expression on peripheral blood mononuclear cells. Mean fluorescence intensity (MFI) of Sca-1 on B220+ cells is shown. Each bar represents the mean, and error bars indicate SE. Data are representative of two or more independent experiments. *, P < 0.05 using the Student's t test.
###end p 12
###begin p 13
###xml 149 151 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 306 314 306 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 E</xref>
###xml 415 417 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
###xml 502 505 502 505 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 513 521 513 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 E</xref>
###xml 574 575 574 575 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 583 584 583 584 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 710 713 710 713 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 726 729 726 729 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 736 744 736 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 E</xref>
###xml 282 286 <span type="species:ncbi:10090">mice</span>
###xml 507 511 <span type="species:ncbi:10090">mice</span>
###xml 730 734 <span type="species:ncbi:10090">mice</span>
The increase in IFN-I after TMPD treatment is not limited to the peritoneal cavity, as the IFN signature is also detectable in the peripheral blood (22). We found that surface expression of the IFN-inducible gene Sca-1 (Ly6A/E) on B cells was dramatically up-regulated in wild-type mice treated with TMPD (Fig. 1 E). Although Sca-1 is naturally expressed by certain lymphocyte subsets and hematopoietic stem cells (28), TMPD induced Sca-1 expression in virtually all B cells in wild-type, but not IFNAR-/-, mice (Fig. 1 E). Increased Sca-1 expression was also evident on CD8+ and CD4+ T cells (unpublished data). Similar to the pattern of ISG expression in PECs, the up-regulation of Sca-1 was reduced in MyD88-/- but not TRIF-/- mice (Fig. 1 E), further supporting an essential role of MyD88 in IFN-I production in this model.
###end p 13
###begin p 14
###xml 143 146 143 146 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 154 157 154 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 161 164 161 164 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 176 179 176 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 253 255 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 345 347 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 421 423 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 444 447 440 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mx1</italic>
###xml 452 456 448 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IRF7</italic>
###xml 499 502 495 498 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 507 510 503 506 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 515 518 511 514 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 527 530 523 526 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 537 543 533 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 165 169 <span type="species:ncbi:10090">mice</span>
###xml 224 228 <span type="species:ncbi:10090">mice</span>
###xml 531 535 <span type="species:ncbi:10090">mice</span>
To address whether the cytoplasmic nucleic acid sensors also contribute to TMPD-induced IFN-I production, we tested the effect of TMPD on IPS-1-/- and TNF-/-TBK1-/- mice (TBK-1-/- is embryonically lethal unless crossed with mice deficient of TNF-alpha [29]). IPS-1 is a required adaptor for intracellular viral RNA detection via RIG-I and MDA5 (12), whereas TBK-1 is required for cytoplasmic DNA-induced IFN-I secretion (30). The expression of Mx1 and IRF7 in PECs was comparable in wild-type, IPS-1-/-, TNF-/-TBK-1-/-, and TNF-/- mice (Fig. 2), suggesting that the intracellular nucleic acid-sensing pathways are not required for IFN-I production in this model. The patterns of peritoneal cell influx and Sca-1 expression on peripheral blood lymphocytes were also similar among these strains (unpublished data). Collectively, our data indicate that TMPD-elicited IFN-I production was strictly MyD88 dependent.
###end p 14
###begin p 15
###xml 0 71 0 71 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Cytoplasmic nucleic acid sensors do not contribute to IFN-I production.</bold>
###xml 91 94 91 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mx1</italic>
###xml 99 103 99 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IRF7</italic>
###xml 139 140 139 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 152 155 152 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 157 158 157 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 168 171 168 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 173 174 173 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 188 191 188 191 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 196 199 196 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 201 202 201 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Cytoplasmic nucleic acid sensors do not contribute to IFN-I production. RT-PCR analysis of Mx1 and IRF7 expression in PECs from wild-type (n = 5), IPS-1-/- (n = 5), TNF-/- (n = 2), and TNF-/-TBK-1-/- (n = 4) animals (normalized to peritoneal cells from an untreated wild-type animal). Each bar represents the mean, and error bars indicate SE. Data are representative of two independent experiments.
###end p 15
###begin title 16
TMPD-induced IFN-I production is TLR7 dependent, IC independent
###end title 16
###begin p 17
###xml 202 205 202 205 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 261 264 249 252 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 308 310 296 298 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 462 477 450 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, A and B</xref>
###xml 206 210 <span type="species:ncbi:10090">mice</span>
Because MyD88 mediates IFN-I induction by TLR7 and TLR9, we next investigated which of these innate receptors is responsible for the effect of TMPD. 2 wk after TMPD treatment, the number of PECs in TLR9-/- mice was reduced by approximately20% compared with TLR7-/- and wild-type controls. The numbers of Ly6Chi monocytes and granulocytes were also reduced in the absence of TLR9, whereas the pattern of the cellular influx remained similar to wild-type animals (Fig. 3, A and B).
###end p 17
###begin p 18
###xml 0 51 0 51 <bold xmlns:xlink="http://www.w3.org/1999/xlink">IFN-I production induced by TMPD is TLR7 dependent.</bold>
###xml 100 102 100 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 171 172 171 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 183 186 183 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 188 189 188 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 204 207 204 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 209 210 209 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 289 291 289 291 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 366 369 366 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mx1</italic>
###xml 374 378 374 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IRF7</italic>
###xml 638 639 638 639 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 697 698 697 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 831 832 831 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 216 220 <span type="species:ncbi:10090">mice</span>
IFN-I production induced by TMPD is TLR7 dependent. (A) Comparison of the number of total PECs, Ly6Chi monocytes, and granulocytes 2 wk after TMPD treatment in wild-type (n = 5), TLR7-/- (n = 5), and TLR9-/- (n = 5) mice. (B) Flow cytometry analysis of peritoneal cells (box indicates Ly6Chi monocytes and dashed oval indicates granulocytes). (C) RT-PCR analysis of Mx1 and IRF7 expression in PECs (normalized to peritoneal cells from an untreated wild-type animal) and ELISA quantification of MCP-1 in the peritoneal lavage fluid. (D) Flow cytometry of Sca-1 surface expression on peripheral blood mononuclear cells. MFI of Sca-1 on B220+ cells is shown. Each bar in A and C represents the mean (n > 4 per group), and error bars indicate SE. Data are representative of two independent experiments. *, P < 0.05 using the Student's t test.
###end p 18
###begin p 19
###xml 19 22 19 22 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 66 68 66 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 105 113 105 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 190 193 190 193 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 302 317 302 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, A and B</xref>
###xml 344 345 344 345 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 349 350 349 350 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 416 424 416 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 B</xref>
###xml 491 494 491 494 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 501 512 501 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, A&#8211;D</xref>
###xml 537 540 537 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mx1</italic>
###xml 545 549 545 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IRF7</italic>
###xml 604 607 604 607 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 614 622 614 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 C</xref>
###xml 723 731 723 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 D</xref>
###xml 770 773 770 773 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 783 786 783 786 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 885 888 885 888 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 23 27 <span type="species:ncbi:10090">mice</span>
###xml 194 198 <span type="species:ncbi:10090">mice</span>
###xml 495 499 <span type="species:ncbi:10090">mice</span>
###xml 608 612 <span type="species:ncbi:10090">mice</span>
###xml 696 700 <span type="species:ncbi:10090">mice</span>
###xml 787 791 <span type="species:ncbi:10090">mice</span>
###xml 889 893 <span type="species:ncbi:10090">mice</span>
Interestingly, TLR7-/- mice exhibited a specific reduction of Ly6Chi monocytes in the peritoneal cavity (Fig. 3 A). Despite the decrease in these immature monocytes, total PEC counts in TLR7-/- mice were comparable to wild-type controls because of a significant increase in the number of granulocytes (Fig. 3, A and B). An accumulation of CD11b+Ly6C- residential macrophages was also evident in the absence of TLR7 (Fig. 3 B). These patterns are strikingly similar to those observed in IFNAR-/- mice (Fig. 1, A-D). Indeed, the increased Mx1 and IRF7 expression and MCP-1 production were abrogated in TLR7-/- mice (Fig. 3 C). Up-regulation of Sca-1 expression on B cells was also reduced in these mice after TMPD treatment (Fig. 3 D), recapitulating the findings in MyD88-/- and IFNAR-/- mice. On the contrary, ISG expression in PECs and surface expression of Sca-1 were similar in TLR9-/- mice compared with wild-type controls. These findings suggest that although TLR9 may contribute to the inflammatory response, IFN-I induction by TMPD was mediated primarily by TLR7.
###end p 19
###begin p 20
###xml 157 160 157 160 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 336 340 336 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCL2</italic>
###xml 342 347 342 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCL12</italic>
###xml 349 353 349 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCL7</italic>
###xml 359 365 359 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CXCL10</italic>
###xml 390 393 390 393 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 543 545 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 760 763 760 763 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 770 778 770 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 812 817 812 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CXCL5</italic>
###xml 242 246 <span type="species:ncbi:10090">mice</span>
###xml 394 398 <span type="species:ncbi:10090">mice</span>
###xml 533 541 <span type="species:ncbi:9606">patients</span>
###xml 764 768 <span type="species:ncbi:10090">mice</span>
To further define the role of TLR7 in the inflammatory response to TMPD, we compared the expression of various cytokines and chemokines in wild-type and TLR7-/- animals using a PCR array. After TMPD treatment, peritoneal cells from wild-type mice displayed dramatically higher expression of several IFN-stimulated chemokines, including CCL2, CCL12, CCL7, and CXCL10, in comparison with TLR7-/- mice (Table S1, available at ). This pattern of chemoattractant production is similar to the chemokine signature recently described in SLE patients (31). These observations support the role of TLR7 as the primary mediator of IFN-I production in the TMPD lupus model. Interestingly, consistent with the increased number of peritoneal granulocytes in TMPD-treated TLR7-/- mice (Fig. 3 A), the neutrophil chemoattractant CXCL5 was up-regulated in the absence of TLR7, whereas the expression of other inflammatory mediators was comparable between the groups (Table S1).
###end p 20
###begin p 21
###xml 133 135 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 311 313 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
###xml 487 489 467 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">33</xref>
###xml 585 587 565 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 776 778 744 746 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 790 798 758 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 971 979 935 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 427 432 <span type="species:ncbi:10090">mouse</span>
Several studies have demonstrated that self-RNA present in ICs may act as an endogenous TLR7 ligand causing the production of IFN-I (18, 19). FcgammaRs have been reported to play an essential role in this process by enhancing the internalization of ICs, thereby allowing RNA to interact with TLR7 in endosomes (32). Deficiency of either TLR7 or FcgammaR gamma chain, an integral component of FcgammaRI and FcgammaRIII, renders mouse DCs unable to produce IFN-I in response to lupus ICs (33). Because TMPD induces IFN-I production long before the onset of lupus autoantibodies and ICs (27), we examined the potential role of FcgammaR in the IFN-I response to TMPD. Surface expression of FcgammaRI (CD64) and FcgammaRII/III (CD32/CD16) in TMPD-induced PECs was prominent on Ly6Chi monocytes (Fig. 4 A). FcgammaRs were also expressed by a fraction of granulocytes, whereas lymphocytes and DCs in the peritoneal cavity displayed little surface expression of these receptors (Fig. 4 A).
###end p 21
###begin p 22
###xml 0 70 0 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Fc&#947;RI and Fc&#947;RIII are dispensable for IFN-I induction by TMPD.</bold>
###xml 374 377 354 357 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 408 409 384 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 483 485 459 461 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 195 199 <span type="species:ncbi:10090">mice</span>
###xml 352 356 <span type="species:ncbi:10090">mice</span>
###xml 402 406 <span type="species:ncbi:10090">mice</span>
FcgammaRI and FcgammaRIII are dispensable for IFN-I induction by TMPD. (A) Flow cytometry analysis of FcgammaRI (CD64) and FcgammaRII/III (CD32/CD16) in PEC populations in TMPD-treated wild-type mice (open histograms). Shaded histograms represent staining with isotype control antibodies. (B) Peritoneal cell influx and (C) ISG expression in wild-type mice and FcgammaRI/III-/- (gamma chain-deficient) mice (n = 3 per group) 2 wk after TPMD treatment. Dashed boxes in B indicate Ly6Chi monocytes. Each bar in C represents the mean, and error bars indicate SE. Data are representative of two independent experiments.
###end p 22
###begin p 23
###xml 80 83 68 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 115 117 103 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 191 194 175 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 215 230 199 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4, B and C</xref>
###xml 85 89 <span type="species:ncbi:10090">mice</span>
###xml 209 213 <span type="species:ncbi:10090">mice</span>
We next analyzed the effects of TMPD on FcgammaR gamma chain-deficient (FcgammaR-/-) mice. The accumulation of Ly6Chi monocytes and up-regulation of ISG expression were comparable in FcgammaR-/- and wild-type mice (Fig. 4, B and C). Elevated surface expression of Sca-1 on peripheral blood lymphocytes was also similar between the groups (unpublished data). Collectively, these findings suggest that TMPD elicits IFN-I production through a TLR7-dependent but FcgammaR-independent pathway.
###end p 23
###begin title 24
###xml 4 6 4 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
Ly6Chi monocytes express high levels of TLR7
###end title 24
###begin p 25
###xml 38 42 38 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR7</italic>
###xml 230 232 230 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 249 250 249 250 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 249 250 249 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sup>+</sup></italic>
###xml 254 256 254 256 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 304 305 292 293 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 304 305 292 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sup>+</sup></italic>
###xml 309 310 297 298 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 309 310 297 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sup>+</sup></italic>
###xml 349 350 325 326 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 349 350 325 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sup>+</sup></italic>
###xml 465 467 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 509 510 473 474 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 509 510 473 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sup>+</sup></italic>
###xml 543 544 507 508 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 543 544 507 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sup>+</sup></italic>
###xml 549 550 513 514 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 554 555 518 519 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 554 555 518 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sup>+</sup></italic>
###xml 112 116 <span type="species:ncbi:10090">mice</span>
Next, we examined the distribution of TLR7 expression in the inflammatory infiltrate induced by TMPD. PECs from mice treated with TMPD 2 wk earlier were sorted into four distinct populations based on surface marker phenotype: Ly6Chi monocytes (CD11b+Ly6Chi; approximately30% of PECs), granulocytes (CD11b+Ly6G+; approximately30% of PECs), DCs (CD11c+; approximately2% of PECs), and a negative fraction containing mainly B and T lymphocytes. As reported previously (27), the DC fraction consisted of >80% CD11b+ myeloid DCs, and few PDCs (CD11c+CD11b-B220+) were present.
###end p 25
###begin p 26
###xml 35 37 35 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 75 79 75 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR7</italic>
###xml 116 124 116 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">34</xref>
###xml 308 312 308 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR7</italic>
###xml 338 340 338 340 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 390 394 390 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR7</italic>
###xml 479 483 479 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR3</italic>
###xml 488 492 488 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR9</italic>
###xml 502 506 502 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR4</italic>
###xml 561 569 561 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
Quantitative PCR revealed that Ly6Chi monocytes expressed higher levels of TLR7 than other peritoneal cell subsets (Fig. 5 A). Prominent expression of the chemokine receptor CCR2 is consistent with their immature monocytic phenotype, as reported previously (34). In striking contrast, elevated expression of TLR7 was not a feature of Ly6Chi monocytes in the spleen or bone marrow. Although TLR7 expression also was found on other PEC subsets, DCs displayed greater expression of TLR3 and TLR9, whereas TLR4 transcripts were predominantly found in granulocytes (Fig. 5 A).
###end p 26
###begin p 27
###xml 4 6 4 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 0 45 0 45 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Ly6C<sup>hi</sup> monocytes express high levels of TLR7.</bold>
###xml 123 125 123 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 452 454 452 454 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 472 473 472 473 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 201 205 <span type="species:ncbi:10090">mice</span>
###xml 281 285 <span type="species:ncbi:10090">mice</span>
Ly6Chi monocytes express high levels of TLR7. (A) RT-PCR analysis of TLR expression in sorted PEC populations, splenic Ly6Chi monocytes, and bone marrow monocyte precursors from wild-type TMPD-treated mice. (B) RT-PCR analysis of TLR7 and TLR9 expression in PECs from TMPD-treated mice 48 h after i.p. injection of PBS or clo-lip. Each bar represents the mean, and error bars indicate SE. (C) ELISA for MCP-1 and IL-6 produced by sorted peritoneal Ly6Chi monocytes (5 x 104 cells/well) 24 h after TLR ligand stimulation. Wedges denote increasing concentrations of LPS, R848, and CpG DNA (100 ng/ml, 1 mug/ml, and 10 mug/ml), and poly I:C (200 ng/ml, 2 mug/ml, and 20 mug/ml). Data are representative of two independent experiments.
###end p 27
###begin p 28
###xml 49 51 49 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 158 162 158 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR7</italic>
###xml 214 218 214 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR9</italic>
###xml 252 260 252 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 B</xref>
###xml 303 305 303 305 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 360 362 360 362 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 468 476 468 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 C</xref>
###xml 662 664 661 663 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 725 733 724 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 C</xref>
###xml 904 906 903 905 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 998 1002 997 1001 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR7</italic>
In line with these findings, when peritoneal Ly6Chi monocytes were depleted by i.p. injection of clodronate-containing liposomes (clo-lip), the expression of TLR7 by PECs was greatly reduced, whereas the levels of TLR9 transcripts remained unaffected (Fig. 5 B). We further analyzed the response of Ly6Chi monocytes to various TLR ligands in vitro. Sorted Ly6Chi monocytes secreted large amounts of MCP-1 and IL-6 when co-cultured with the synthetic TLR7 ligand R848 (Fig. 5 C). They also responded to the TLR4 ligand LPS, albeit less strongly even at the highest dose of LPS tested (10 mug/ml). Consistent with their low levels of TLR3 and TLR9 expression, Ly6Chi monocytes exhibited weak responses to poly I:C and CpG DNA (Fig. 5 C). In contrast, isolated granulocytes did not produce measurable amounts of MCP-1 or IL-6 in response to any TLR ligands used in this study (unpublished data). Hence, Ly6Chi monocytes recruited to the peritoneal cavity after TMPD treatment expressed high levels of TLR7 and actively responded to TLR7 ligands.
###end p 28
###begin title 29
The Y-linked autoimmune accelerating (Yaa) locus amplifies the effects of TMPD
###end title 29
###begin p 30
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib35">35</xref>
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">36</xref>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 228 232 228 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR7</italic>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib39">39</xref>
###xml 296 300 296 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR7</italic>
###xml 558 560 558 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
###xml 562 564 562 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib39">39</xref>
###xml 598 602 598 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR7</italic>
###xml 704 706 704 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">40</xref>
###xml 121 126 <span type="species:ncbi:10090">mouse</span>
###xml 349 355 <span type="species:ncbi:9606">humans</span>
###xml 360 364 <span type="species:ncbi:10090">mice</span>
###xml 484 488 <span type="species:ncbi:10090">mice</span>
The Yaa locus is essential for the spontaneous development of autoantibodies and glomerulonephritis in the BXSB model of mouse lupus (35). Yaa also accelerates disease onset in other lupus-prone strains (36, 37). Interestingly, TLR7 is among the 17 genes found in the Yaa locus (38, 39). Because TLR7 is normally located on the X chromosome in both humans and mice, males possess one copy of the gene, whereas a similar gene dosage is achieved in females through X inactivation. Male mice with the Yaa locus, however, have two functional copies of the gene (38, 39). A recent study showed that the TLR7 gene duplication alone was responsible for the autoimmune features associated with the Yaa mutation (40).
###end p 30
###begin p 31
###xml 197 200 197 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 254 259 254 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/Yaa</sup>
###xml 299 301 299 301 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 364 372 364 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 A</xref>
###xml 523 531 523 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 B</xref>
###xml 218 222 <span type="species:ncbi:10090">mice</span>
Because TMPD induces IFN-I production via TLR7, we asked whether the effects of the adjuvant oil are more pronounced in the presence of the Yaa locus. Compared with female controls (designated TLR7+/+), BXSB x B6 male mice carrying the Yaa mutation (TLR7+/Yaa) exhibited greater accumulation of Ly6Chi monocytes in the peritoneal cavity 2 wk after TMPD treatment (Fig. 6 A). Importantly, increasing the gene dosage of TLR7 was associated with significantly higher production of IFN-I, assessed by measuring ISG expression (Fig. 6 B). In contrast, the IFN-I response to TMPD was similar between males and females in wild-type strains, including C57BL/6, BALB/c, and 129Sv (unpublished data).
###end p 31
###begin p 32
###xml 0 43 0 43 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Yaa mutation amplifies the effects of TMPD.</bold>
###xml 150 153 150 153 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 169 174 169 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/Yaa</sup>
###xml 213 215 213 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 378 379 378 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 176 180 <span type="species:ncbi:10090">mice</span>
###xml 419 423 <span type="species:ncbi:10090">mice</span>
Yaa mutation amplifies the effects of TMPD. (A) Flow cytometry of peritoneal cells and (B) RT-PCR analysis of ISG expression in BXSB x B6 female (TLR7+/+) and male (TLR7+/Yaa) mice. Dashed boxes in A indicate Ly6Chi monocytes. Each bar in B represents the mean, and error bars indicate SE. Data are representative of two independent experiments. *, P < 0.05 using the Student's t test. (C) Survival curve for male BXSB mice after PBS or TMPD treatment (arrow denotes treatment at 8-10 wk of age).
###end p 32
###begin p 33
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib35">35</xref>
###xml 171 179 171 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 C</xref>
We further examined the long-term effect of TMPD treatment in the BXSB model. Consistent with previous studies (35), BXSB males died prematurely beginning at 5 mo of age (Fig. 6 C). Mortality was significantly accelerated when a single dose of TMPD was administered i.p. at 8-10 wk of age. 60% of TMPD-treated animals succumbed by 5 mo of age compared with 20% in the control group. Although 5 out of 10 PBS-treated animals survived until 7 mo, only 1 out of 10 in the TMPD-treated group remained. Thus, not only was the induction of IFN-I accentuated by the Yaa mutation, TMPD treatment also hastened disease progression in the BXSB model of lupus.
###end p 33
###begin title 34
TLR7 is essential for the development of autoantibodies against RNA-associated antigens
###end title 34
###begin p 35
###xml 25 28 25 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lpr</italic>
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib41">41</xref>
###xml 284 287 284 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 460 462 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib42">42</xref>
###xml 550 558 550 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 A</xref>
###xml 613 616 613 616 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 744 746 744 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib43">43</xref>
###xml 796 799 796 799 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 806 814 806 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 B</xref>
###xml 29 33 <span type="species:ncbi:10090">mice</span>
###xml 288 292 <span type="species:ncbi:10090">mice</span>
###xml 472 476 <span type="species:ncbi:10090">mice</span>
###xml 617 621 <span type="species:ncbi:10090">mice</span>
###xml 800 804 <span type="species:ncbi:10090">mice</span>
A recent study using MRL-lpr mice showed that TLR7 is required for the development of anti-Sm antibodies (41). To assess whether TLR7 is also involved in autoantibody production in the TMPD model of lupus, we compared the long-term response to TMPD in wild-type BALB/c and BALB/c.TLR7-/- mice. No mortality was found in either group and only mild proteinuria was detected by 24 wk after treatment (Fig. S1, available at ). Comparable to previous observations (42), BALB/c mice displayed significant hypergammaglobulinemia 24 wk after TMPD treatment (Fig. 7 A). The increase in serum IgG was reduced by 50% in TLR7-/- mice, whereas IgM levels were similar between the groups. Consistent with the prominent role of IFN-I in IgG2a isotype switch (43), a profound reduction of IgG2a was found in TLR7-/- mice (Fig. 7 B). IgG1 and IgG2b levels were also mildly reduced in the absence of TLR7, whereas IgG3 was slightly increased.
###end p 35
###begin p 36
###xml 0 97 0 97 <bold xmlns:xlink="http://www.w3.org/1999/xlink">TLR7 promotes hypergammaglobulinemia and mediates the development of anti-nRNP/Sm autoantibodies.</bold>
###xml 162 165 162 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 167 168 167 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 196 197 196 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 351 352 351 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 629 630 629 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 674 676 674 676 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 204 208 <span type="species:ncbi:10090">mice</span>
TLR7 promotes hypergammaglobulinemia and mediates the development of anti-nRNP/Sm autoantibodies. (A) Total IgM and IgG and (B) IgG subclass levels in BALB/c.TLR7-/- (n = 8) and wild-type BALB/c (n = 12) mice before and 24 wk after TMPD treatment. Bars represent the mean, and error bars indicate SE. *, P < 0.05; and **, P < 0.001 using the unpaired t test. (C) Fluorescent ANA titers (titration emulation) and (D) anti-nRNP/Sm IgG levels (antigen-capture ELISA) at 12 and 24 wk after TMPD treatment. Horizontal lines indicate medians. *, P < 0.05 using the Mann-Whitney U test. (E) Immunoprecipitation of serum autoantibodies (n = 6 per group) using nuclear extracts from 35S-labeled K562 cells (12.5% polyacrylamide gel). Arrows indicate components of nRNP/Sm, and numerical values denote the molecular mass (kD).
###end p 36
###begin p 37
###xml 167 182 167 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7, C and D</xref>
###xml 225 228 225 228 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 304 319 304 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7, C and D</xref>
###xml 338 341 338 341 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 365 368 365 368 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 520 528 520 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 C</xref>
###xml 544 547 544 547 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 730 733 730 733 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 759 767 759 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 D</xref>
###xml 867 869 867 869 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 1025 1028 1025 1028 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1035 1043 1035 1043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 E</xref>
###xml 62 66 <span type="species:ncbi:10090">mice</span>
###xml 369 373 <span type="species:ncbi:10090">mice</span>
###xml 734 738 <span type="species:ncbi:10090">mice</span>
###xml 1029 1033 <span type="species:ncbi:10090">mice</span>
As early as 12 wk after TMPD treatment, 8 out of 12 wild-type mice developed detectable serum levels of antinuclear antibodies (ANAs) and anti-nRNP/Sm autoantibodies (Fig. 7, C and D). In contrast, only one animal in the TLR7-/- group showed a low titer ANA and none developed autoantibodies to nRNP/Sm (Fig. 7, C and D). Similar to IFNAR-/- animals (22), most TLR7-/- mice exhibited low levels of ANAs of unknown specificity by 24 wk after treatment, but their titers remained significantly lower than BALB/c controls (Fig. 7 C). A single TLR7-/- animal with a high ANA titer (1:1,280) produced autoantibodies against DNA/chromatin (unpublished data). In contrast, autoantibodies against nRNP-Sm remained undetectable in all TLR7-/- mice at this time point (Fig. 7 D). We further confirmed the autoantibody profile by immunoprecipitation using nuclear extracts from 35S-labeled K562 cells. Consistent with the findings by ELISA, autoantibodies against various components of nRNP/Sm (A-G) were found in wild-type but not TLR7-/- mice (Fig. 7 E).
###end p 37
###begin p 38
###xml 140 142 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 194 196 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 223 226 199 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 233 241 209 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 A</xref>
###xml 366 368 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib44">44</xref>
###xml 485 493 461 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 B</xref>
###xml 130 138 <span type="species:ncbi:9606">patients</span>
###xml 188 192 <span type="species:ncbi:10090">mice</span>
###xml 227 231 <span type="species:ncbi:10090">mice</span>
Immunoprecipitation studies also revealed that autoantibodies against the Su antigen, which develops in approximately20% of lupus patients (26) and approximately50% of TMPD-treated BALB/c mice (26), were not induced in TLR7-/- mice (Fig. 8 A). A recent study identified the Su antigen as an RNA-binding component of the microRNA pathway known as argonaute 2 (ago2) (44). ELISA using recombinant ago2 confirmed that the development of autoantibodies against Su/ago2 was TLR7 dependent (Fig. 8 B), suggesting that the autoimmune response to microRNA-associated antigens is also mediated by TLR7. Collectively, in addition to its role in mediating IFN-I production, TLR7 is essential for the generation of autoantibodies against RNA-associated antigens (nRNP/Sm and Su/ago2) in TMPD-induced lupus.
###end p 38
###begin p 39
###xml 0 68 0 68 <bold xmlns:xlink="http://www.w3.org/1999/xlink">TLR7 is required for the development of anti-Su/ago2 autoantibodies.</bold>
###xml 168 169 168 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
TLR7 is required for the development of anti-Su/ago2 autoantibodies. (A) Immunoprecipitation of serum autoantibodies 24 wk after TMPD treatment (8% polyacrylamide gel; n = 6 per group). Arrows indicate the 100-kD Su antigen, and numerical values denote the molecular mass (kD). (B) Anti-Su/ago levels at baseline and 24 wk after TMPD treatment measured by ELISA using recombinant ago2 protein. Horizontal lines indicate medians. *, P < 0.05 using the Mann-Whitney U test.
###end p 39
###begin title 40
TMPD enhances TLR7 stimulation in vitro
###end title 40
###begin p 41
###xml 637 645 637 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9 A</xref>
###xml 827 835 824 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9 A</xref>
###xml 362 368 <span type="species:ncbi:9913">bovine</span>
###xml 551 556 <span type="species:ncbi:10090">mouse</span>
To further investigate the link between TMPD treatment and TLR7 activation, we studied the effect of TMPD in vitro. Although TMPD has been used for decades, mechanistic studies on its cellular effects have been limited by the hydrocarbon's poor immiscibility in aqueous solutions. We found that this problem could be circumvented by first mixing TMPD with fetal bovine serum before the addition of culture medium (unpublished data). Unlike stimulation with R848, a TLR7 ligand that elicits IL-6 production and co-stimulatory molecule up-regulation in mouse J774 macrophages, the addition of TMPD in vitro did not induce these responses (Fig. 9 A and not depicted). TMPD solubilized in nonphysiological solvents such as ethanol, DMSO, mannide monooleate, or beta-cyclodextrin was also ineffective in triggering TLR7 activation (Fig. 9 A), suggesting that TMPD itself is not a ligand for TLR7.
###end p 41
###begin p 42
###xml 0 40 0 40 <bold xmlns:xlink="http://www.w3.org/1999/xlink">TMPD enhances TLR7 stimulation in vitro.</bold>
TMPD enhances TLR7 stimulation in vitro. (A) ELISA for IL-6 production in J774 cells cultured in the presence of 1 mug/ml R848, 1 mug/ml TMPD incorporated in serum, or 300 muM TMPD solubilized in ethanol, DMSO, mannide monooleate (MM), or beta-cyclodextrin (beta-CyD). ND, not detectable. (B) ELISA (IL-6 and MCP-1) and flow cytometric analysis (CD80 and CD86) in J774 cells or (C) bone marrow-derived macrophages cultured for 20 h with or without TMPD and stimulated with PBS, 1 mug/ml R848, or 2 mug/ml ODN 2395 for 24 h. MFI values are provided. Shaded histograms represent J774 cells cultured in medium alone, whereas open histograms represent cells treated with TMPD. (D) Comparison of IL-6 production and CD80 expression (MFI) in J774 cells cultured with various hydrocarbon oils and stimulated with PBS or R848. (E) Flow cytometry and RT-PCR analysis of TLR7 expression in J774 cells cultured with or without TMPD for 20 h. Each bar represents the mean, and error bars indicate SE. Data are representative of three or more independent experiments.
###end p 42
###begin p 43
###xml 238 246 238 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9 B</xref>
###xml 406 414 406 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9 C</xref>
###xml 620 628 620 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9 D</xref>
###xml 894 902 894 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9 E</xref>
However, exposure to TMPD dramatically enhanced the response to subsequent stimulation with TLR7 ligands. R848-induced IL-6 production and co-stimulatory molecule up-regulation were augmented in J774 cells pretreated overnight with TMPD (Fig. 9 B). Similar enhancement of chemokine and cytokine production was found in bone marrow-derived macrophages stimulated with R848 but not the TLR9 ligand ODN 2395 (Fig. 9 C). Importantly, these observations were specific to TMPD, as treatment with other hydrocarbon oils that do not induce lupus, such as medicinal mineral oil and squalene, did not enhance stimulation by R848 (Fig. 9 D). We further examined whether TMPD augments the response to TLR7 ligands by altering the expression or location of TLR7. TLR7 remained exclusively intracellular regardless of TMPD treatment, and its expression levels were not affected at the protein or mRNA level (Fig. 9 E). Moreover, TMPD treatment did not enhance endocytosis of FITC-dextran or phagocytosis of latex beads or apoptotic cells (Fig. S2, available at ), suggesting that accelerated uptake of ligands is also unlikely to explain our findings. Collectively, these data indicate that TMPD is not a direct ligand for TLR7 but instead acts to enhance the response to TLR7 stimulation.
###end p 43
###begin title 44
DISCUSSION
###end title 44
###begin p 45
###xml 313 314 313 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 315 316 315 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 318 320 318 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib45">45</xref>
###xml 124 132 <span type="species:ncbi:9606">patients</span>
Recent studies strongly suggest a link between elevated IFN-I production and the pathogenesis of SLE. More than half of SLE patients display increased expression of ISGs, often in association with active disease and autoantibodies against snRNPs and DNA, as well as renal involvement and endothelial dysfunction (2-6, 45). However, the exact cause of IFN-I dysregulation in lupus remains controversial, and it is unclear whether IFN-I overproduction promotes autoantibody production or vice versa.
###end p 45
###begin p 46
###xml 152 154 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">46</xref>
###xml 364 366 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 423 425 423 425 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 454 456 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 786 788 786 788 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 55 60 <span type="species:ncbi:9606">human</span>
###xml 279 283 <span type="species:ncbi:10090">mice</span>
The TMPD model of lupus recapitulates many features of human SLE, including glomerulonephritis, arthritis, and autoantibodies against dsDNA and snRNPs (25, 26). Moreover, like SLE, TMPD-induced lupus is more severe in females than males (46). We recently found that TMPD-treated mice exhibit the IFN signature and that their lupus is dependent on IFN-I signaling (22). The major IFN-I-producing cells in TMPD lupus are Ly6Chi monocytes rather than PDCs (27). In this study, we show that TMPD triggers IFN-I production via the TLR7-MyD88 pathway. Our data also exclude a major role of other pathways of IFN-I production, including TLR9, TLR3-TLR4-TRIF, RIG-I-Mda5-IPS-1, and DAI-TBK1. Although there was a strict requirement for TLR7 and MyD88, expression of ISGs and recruitment of Ly6Chi monocytes in response to TMPD was unexpectedly independent of FcgammaRs.
###end p 46
###begin p 47
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib47">47</xref>
###xml 527 529 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 531 533 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib47">47</xref>
###xml 623 625 619 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 627 629 623 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
###xml 631 633 627 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib48">48</xref>
###xml 786 788 774 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">33</xref>
###xml 570 575 <span type="species:ncbi:9606">human</span>
###xml 684 689 <span type="species:ncbi:9606">human</span>
###xml 728 733 <span type="species:ncbi:10090">mouse</span>
The innate sensors TLR7 and TLR9 have been implicated in SLE because of their ability to recognize endogenous nucleic acids and trigger IFN-I production (47). Mammalian nucleic acids are generally weak TLR ligands because of their inability to reach the endosomal compartment where TLR7 and TLR9 are localized. When they form ICs with lupus autoantibodies (anti-Sm/RNP or anti-dsDNA), endogenous nucleic acids may be delivered more efficiently to endosomes because of uptake by FcgammaRs, stimulating IFN-I production by PDCs (17, 47). This model for IFN-I induction in human SLE is supported by numerous in vitro studies (19, 32, 48). Although FcgammaRIIa mediates the activation of human PDCs, ICs trigger IFN-I production by mouse PDCs in a TLR7- and FcgammaRI/III-dependent manner (33).
###end p 47
###begin p 48
###xml 476 478 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 775 777 751 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib49">49</xref>
###xml 607 611 <span type="species:ncbi:10090">mice</span>
###xml 769 773 <span type="species:ncbi:10090">mice</span>
However, it is not known whether the development of antiribonucleoprotein autoantibodies is a cause of IFN-I dysregulation or a consequence of it. Therapeutic use of IFN-alpha can induce many features of SLE, including anti-dsDNA antibodies, suggesting that IFN-I dysregulation occurs upstream of IC formation. Consistent with that view, IFN-I up-regulation in the TMPD model occurs within the first 2 wk of treatment, more than 2 mo before the onset of lupus autoantibodies (27). FcgammaRI and FcgammaRIII were not required for the IFN-I response to TMPD because it was unaffected in gamma chain-deficient mice. Moreover, a previous study also showed that the absence of FcgammaRI/III or FcgammaRIIb does not affect anti-Sm/RNP autoantibody production in TMPD-treated mice (49). Although IC formation and FcgammaRs are not required to initiate IFN-I production, we cannot exclude the possibility that they amplify IFN-I secretion and accelerate disease progression subsequent to the development of autoantibodies.
###end p 48
###begin p 49
###xml 84 87 84 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lpr</italic>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib41">41</xref>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib50">50</xref>
###xml 294 297 294 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lpr</italic>
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib51">51</xref>
###xml 380 383 380 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lpr</italic>
###xml 425 427 425 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib52">52</xref>
###xml 56 61 <span type="species:ncbi:10090">mouse</span>
###xml 88 92 <span type="species:ncbi:10090">mice</span>
###xml 298 302 <span type="species:ncbi:10090">mice</span>
A pathogenic role of TLR7 has been described in several mouse models of SLE. In MRL-lpr mice, TLR7 ligands accelerate the onset of glomerulonephritis, whereas deletion of TLR7 abrogates the development of anti-Sm autoantibodies and lessens the severity of kidney disease (41, 50). Lupus in MRL-lpr mice has been reported to be ameliorated, not exacerbated, by IFN-I (51), and the lpr defect prevents induction of TMPD lupus (52).
###end p 49
###begin p 50
###xml 226 228 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib53">53</xref>
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib54">54</xref>
###xml 535 538 531 534 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 633 635 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
###xml 637 639 633 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib39">39</xref>
###xml 750 752 746 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">40</xref>
###xml 925 928 921 924 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lpr</italic>
###xml 936 938 932 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib41">41</xref>
###xml 209 224 <span type="species:ncbi:10090">transgenic mice</span>
###xml 407 411 <span type="species:ncbi:10090">mice</span>
###xml 555 559 <span type="species:ncbi:10090">mice</span>
###xml 1024 1028 <span type="species:ncbi:10090">mice</span>
###xml 1077 1081 <span type="species:ncbi:10090">mice</span>
Dual engagement of TLR7 and the B cell receptor can directly activate autoreactive B cells in the AM14 model, and TLR7 is also required for the spontaneous production of autoantibodies against ssRNA in 564Igi transgenic mice (53, 54). The connection between TLR7 and the generation of RNA-associated autoantibodies is further illustrated by the recent demonstration of a duplication of the TLR7 gene in Yaa mice. The presence of the Yaa cluster was sufficient to induce production of RNA-associated autoantibodies in C57BL/6 FcgammaIIB-/- and C57BL6.Sle1 mice, two autoimmune strains that normally lack these antibody specificities (38, 39). TLR7, and not the other 16 genes affected by the Yaa mutation, is responsible for the autoimmune pathology (40). However, increased IFN-I production has not been reported in these models. Our findings indicate that TLR7 also plays an essential role in TMPD lupus. Similar to the MRL-lpr model (41), TLR7 is required for the generation of anti-nRNP/Sm autoantibodies in TMPD-treated mice. Importantly, the IFN signature in TMPD-treated mice, which is established within 2 wk of treatment (long before the appearance of anti-nRNP autoantibodies), was abolished in the absence of TLR7. In contrast, the effects of TMPD were amplified in the presence of the Yaa locus. Therefore, this study provides evidence for direct in vivo involvement of TLR7 in the induction of IFN-I, even in the absence of autoantibodies and ICs.
###end p 50
###begin p 51
###xml 34 36 34 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 212 214 212 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 430 432 430 432 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 690 692 690 692 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 919 921 919 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">40</xref>
###xml 962 964 962 964 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 1050 1053 1050 1053 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1060 1063 1060 1063 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1074 1077 1074 1077 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1165 1169 1165 1169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCL2</italic>
###xml 1171 1175 1171 1175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCL7</italic>
###xml 1181 1186 1181 1186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCL12</italic>
###xml 1319 1321 1319 1321 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 459 463 <span type="species:ncbi:10090">mice</span>
###xml 913 917 <span type="species:ncbi:10090">mice</span>
###xml 1078 1082 <span type="species:ncbi:10090">mice</span>
We have previously shown that Ly6Chi monocytes are a major source of IFN-I in the TMPD model (27). Depletion of monocytes but not DCs reduced IFN-I production and ISG expression. In this study, we found that Ly6Chi monocytes also express higher levels of TLR7 and display a greater response in vitro to R848 than to other TLR ligands. Although TLR7 is normally found on monocytes and macrophages, its expression on peritoneal Ly6Chi monocytes in TMPD-treated mice was several fold higher than on splenic or bone marrow monocytes. In contrast, DCs in the peritoneal exudate displayed lower levels of TLR7 and more prominent TLR3 and TLR9 expression. The high expression level of TLR7 by Ly6Chi monocytes may be of critical importance in the pathogenesis of TMPD lupus, as a recent study demonstrated that increased gene dosage of TLR7 is sufficient to trigger anti-RNA antibodies and glomerulonephritis in C57BL/6 mice (40). Interestingly, the recruitment of Ly6Chi monocytes to the peritoneum seems to be partially dependent on IFN-I, as seen in TLR7-/-, MyD88-/-, and IFNAR-/- mice. TLR7 signaling also induces the expression of several IFN-stimulated chemokines (CCL2, CCL7, and CCL12), suggesting that the mechanism may involve enhanced production of monocyte chemoattractants, creating an amplification loop of Ly6Chi monocyte recruitment and IFN-I production. The recruitment of DCs and granulocytes, on the other hand, was not dependent on IFN-I or TLR7.
###end p 51
###begin p 52
###xml 744 746 744 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 748 750 748 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib55">55</xref>
###xml 872 874 872 874 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 630 634 <span type="species:ncbi:10090">Mice</span>
The mechanism linking TMPD to the activation of TLR7 has been partially elucidated by our studies. The hydrocarbon structure of TMPD is distinct from known TLR7 ligands, including ssRNA, R848, loxoribine, and other guanosine analogues. Indeed, our in vitro studies showed that TMPD did not activate TLR7 directly but instead augmented the inflammatory response to TLR7 ligands such as R848. The ability of hydrocarbon oils to enhance TLR7 stimulation in vitro seems related to their ability to induce lupus-like disease in vivo. Unlike TMPD, squalene and medicinal mineral oil were ineffective in augmenting the response to R848. Mice treated with squalene and mineral oil do not display the IFN signature and few develop lupus autoantibodies (27, 55). TMPD appears to enhance activation via the TLR7 pathway in at least two ways: (a) by augmenting the recruitment of Ly6Chi monocytes, which express high levels of TLR7, and (b) by enhancing the intrinsic responsiveness of TLR7 to its ligands. Additional studies will be needed to elucidate whether TMPD causes increased uptake of apoptotic/necrotic material, enhancing the recognition of TLR7 ligands, or if TMPD interacts with components of the TLR7 signaling pathway, augmenting the response to receptor-ligand interactions.
###end p 52
###begin p 53
###xml 525 527 525 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib56">56</xref>
###xml 528 530 528 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib58">58</xref>
###xml 641 643 641 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib59">59</xref>
###xml 649 653 649 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR7</italic>
###xml 666 668 666 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib60">60</xref>
Although the underlying mechanisms are distinct, the pathological consequences of excess TLR7 activation are shared by TMPD-induced lupus and the Yaa model. An important unanswered question that encompasses both models is the nature of the exogenous or endogenous ligands responsible for activating the TLR7 pathway. It is possible that chronic TMPD-stimulated inflammation provides a persistent source of autoantigens from apoptotic cells and that endogenous TLR7 ligands such as the U1 RNA component of the Sm/RNP antigen (56-58) trigger the first wave of IFN-I production. Downstream signaling events may elicit further IFN-I production (59) and TLR7 expression (60), culminating in a positive feedback cycle that promotes autoimmunity by persistently activating TLR7. It remains to be verified experimentally whether or not RNA-associated autoantigens from apoptotic cells are key mediators of Yaa- and TMPD-induced lupus in vivo.
###end p 53
###begin p 54
###xml 279 282 279 282 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 292 295 292 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 296 300 <span type="species:ncbi:10090">mice</span>
It is noteworthy that besides activating IFN-I production via TLR7, TMPD also induced the recruitment of granulocytes via an MyD88-dependent but TLR7-independent pathway. The number of peritoneal granulocytes actually increased in the absence of IFN-I production, as seen in TLR7-/- and IFNAR-/- mice. MyD88 is used in the signaling pathways of other cytokines (IL-1 and IL-18) and TLRs (except TLR3), which are potential mediators of granulocyte recruitment in this model.
###end p 54
###begin p 55
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib61">61</xref>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib62">62</xref>
###xml 475 477 475 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib53">53</xref>
###xml 604 606 604 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib63">63</xref>
###xml 149 153 <span type="species:ncbi:10090">mice</span>
Finally, our findings may shed light on other pathology induced by TMPD. The development of plasmacytomas after i.p. injection of TMPD in BALB/cAnPt mice was first described more than three decades ago (61). Subsequently TMPD was used to enhance monoclonal antibody production by hybridomas (62). How TMPD elicits these effects is incompletely understood, although IL-6 has been implicated. Interestingly, although TLR7 can trigger B cell activation and antibody production (53), IFN-I plays an important role in antibody class switching and promotes plasma cell differentiation in the presence of IL-6 (63). Whether TLR7 activation and IFN-I production are involved in the pathogenesis of plasmacytomas and enhancement of antibody production by hybridomas warrants further investigation.
###end p 55
###begin title 56
MATERIALS AND METHODS
###end title 56
###begin title 57
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice.
###end title 57
###begin p 58
###xml 5 8 5 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 14 17 14 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 23 26 23 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 32 35 32 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 46 49 46 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 120 123 120 123 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 128 131 128 131 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 136 139 136 139 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 143 146 143 146 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 221 222 221 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 224 225 224 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 231 233 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib64">64</xref>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib66">66</xref>
###xml 320 323 320 323 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 638 641 634 637 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1185 1187 1180 1182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib67">67</xref>
###xml 50 54 <span type="species:ncbi:10090">mice</span>
###xml 147 151 <span type="species:ncbi:10090">mice</span>
###xml 399 403 <span type="species:ncbi:10090">mice</span>
###xml 642 646 <span type="species:ncbi:10090">mice</span>
###xml 666 670 <span type="species:ncbi:10090">mice</span>
###xml 792 796 <span type="species:ncbi:10090">mice</span>
MyD88-/-, TRIF-/-, TLR7-/-, TLR9-/-, and IFNAR-/- mice (backcrossed >7 generations to the C57BL/6 background), and IPS-1-/-, TNF-/-, TNF-/-TBK1-/- mice (on a mixed 129Sv/B6 background) have all been described previously (7, 8, 29, 64-66). Wild-type C57BL/6 and heterozygous littermates were used as controls. BALB/c.TLR7-/- (backcrossed >8 generations to the BALB/c background) and wild-type BALB/c mice were used for long-terms studies of autoantibody production. Animals were bred and maintained in a specific pathogen-free facility of the Research Institute for Microbial Diseases, Osaka University. C57BL/6 wild-type and FcgammaRI/III-/- mice (Taconic) and BXSB mice (The Jackson Laboratory) were maintained in a specific pathogen-free facility at the University of Florida. BXSB x B6 F1 mice were generated by breeding BXSB males with C57BL/6 females. 12-16-wk-old animals received a single i.p. injection of 0.5 ml TMPD (Sigma-Aldrich). Blood samples were obtained before TMPD treatment and weekly thereafter. Peritoneal cells, spleen, and blood were harvested 2 wk after treatment. Monocyte depletion was performed by i.p. injection of 200 mul clo-lip, as previously described (67). These studies were approved by the University of Florida Institutional Animal Care and Use Committee and the Osaka University Animal Care and Use Committee.
###end p 58
###begin title 59
Real-time quantitative PCR (RT-PCR).
###end title 59
###begin p 60
###xml 46 48 46 48 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 92 93 92 93 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 120 123 120 123 <sc xmlns:xlink="http://www.w3.org/1999/xlink">zol</sc>
RT-PCR was performed as previously described (24). In brief, total RNA was extracted from 106 peritoneal cells using TRIzol reagent (Invitrogen), and cDNA was synthesized using the Superscript II First-Strand Synthesis kit (Invitrogen) according to the manufacturer's protocol. SYBR green RT-PCR analysis was performed using a thermocycler (Opticon II; MJ Research). Amplification conditions were as follows: 95degreesC for 10 min, followed by 45 cycles of 94degreesC for 15 s, 60degreesC for 25 s, and 72degreesC for 25 s. After the final extension (72degreesC for 10 min), a melting-curve analysis was performed to ensure specificity of the products. Primers used in this study are listed in Table S2 (available at ). Cytokine/chemokine PCR array (Superarray) analysis was performed using a sequence detector (ABI 7700; Applied Biosystems) according to the manufacturer's protocols.
###end p 60
###begin title 61
Flow cytometry and cell sorting.
###end title 61
###begin p 62
###xml 680 682 680 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib50">50</xref>
###xml 1038 1040 1038 1040 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 1057 1058 1057 1058 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1062 1064 1062 1064 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 1088 1089 1088 1089 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1115 1116 1115 1116 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1120 1121 1120 1121 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 366 371 <span type="species:ncbi:10090">mouse</span>
###xml 690 696 <span type="species:ncbi:9986">rabbit</span>
###xml 702 707 <span type="species:ncbi:10090">mouse</span>
###xml 716 722 <span type="species:ncbi:9986">rabbit</span>
###xml 761 765 <span type="species:ncbi:9925">goat</span>
###xml 771 777 <span type="species:ncbi:9986">rabbit</span>
The following conjugated antibodies were used: anti-CD11b-PE, anti-CD8-allophycocyanin (APC), anti-CD4-FITC, anti-CD11c-PE, anti-B220-PerCPCy5.5, anti-Sca-1-PE, anti-CD64-PE, anti-CD32/16-PE (all from BD), anti-Ly6C-FITC, anti-Ly6C-biotin, and avidin-APC (all from eBioscience). Before surface staining, peritoneal or peripheral blood cells were incubated with anti-mouse CD16/32 (Fc block; BD) for 10 min. Cells were then stained with an optimized amount of primary antibody or the appropriate isotype control for 10 min at room temperature before washing and resuspending in PBS supplemented with 0.1% BSA. Intracellular staining for TLR7 was performed as previously described (50) using rabbit anti-mouse TLR7 or rabbit IgG isotype control (eBioscience) and goat anti-rabbit IgG-FITC (SouthernBiotech). 50,000 events per sample were acquired using a FACSCalibur (BD) and analyzed with FCS Express 3 software (De Novo Software). Cell sorting was performed using a flow cytometer (FACSDiva; BD). Peritoneal, splenic, and bone marrow Ly6Chi monocytes (CD11b+Ly6Chi), peritoneal DCs (CD11c+), and granulocytes (CD11b+Ly6G+) were sorted to >90% purity for cell culture or RNA isolation.
###end p 62
###begin title 63
TLR stimulation.
###end title 63
###begin p 64
###xml 195 196 195 196 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 344 366 344 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella typhimurium</italic>
###xml 426 427 420 421 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 344 366 <span type="species:ncbi:90371">Salmonella typhimurium</span>
Sorted cells resuspended in complete DMEM (containing 10% FCS, 10 mmol/liter Hepes, glutamine, and penicillin/streptomycin plus 10 U/ml heparin) were seeded on 96-well cell-culture plates (5 x 104 cells/well). Cells were stimulated with the doses indicated in the figures of peptidoglycan, poly I:C, R848, CpG ODN2395 (InvivoGen), or LPS (from Salmonella typhimurium; Sigma-Aldrich) and were incubated at 37degreesC in a 5% CO2 atmosphere for 24 h before collecting the supernatant. MCP-1 and IL-6 ELISAs (BD) were performed according to the manufacturer's instructions. Optical density was converted to concentration using standard curves based on recombinant cytokines analyzed by a four-parameter logistic equation (Softmax Pro 3.1 software; MDS Analytical Technologies).
###end p 64
###begin title 65
Cell culture with TMPD.
###end title 65
###begin p 66
###xml 533 534 514 515 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 867 869 845 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib68">68</xref>
###xml 2011 2012 1969 1970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 62 68 <span type="species:ncbi:9913">bovine</span>
###xml 1981 1985 <span type="species:ncbi:10090">mice</span>
1 ml TMPD, mineral oil or squalene was added to 9 ml of fetal bovine serum in a 15-ml polypropylene tube and was rotated for 48 h at 4degreesC. The surface layer of unincorporated hydrocarbon oil was removed by aspiration at the end of the incubation. The amount of TMPD incorporated using this method was approximately1 mug/ml, as determined by gas chromatography/mass spectroscopy (not depicted; Analytical Toxicology Core, University of Florida). J774 cells or bone marrow-derived macrophages were seeded on 24-well plates (5 x 105 cells/well) and cultured overnight in complete DMEM containing 10% FCS with or without hydrocarbon oils. For subsequent stimulation, cells were washed with PBS, and fresh complete medium was added before the addition of TLR ligands. Incorporation of TMPD in DMSO and beta-cyclodextrin (Sigma-Aldrich) has been described previously (68). TMPD (10% vol/vol) also was added to ethanol or mannide monooleate (5% in PBS; Sigma-Aldrich). Solvent alone was used as a control, and a range of TMPD concentrations (3-300 muM) was tested. Endocytosis was quantified by uptake of 5 mug/ml FITC-dextran (Sigma-Aldrich), and phagocytosis by internalization of FITC-labeled microbeads (10:1 beads/cells ratio; Invitrogen) or tetramethylindodicarbocyanine perchlorate (DiD)-labeled apoptotic BW5147 cells (10:1 apoptotic cell/ target cell ratio) after overnight incubation of J774 cells in complete medium with or without TMPD. Apoptosis of BW5147 cells was induced by heat shock in a 45degreesC water bath for 10 min. After 4 h of incubation at 37degreesC, apoptotic cells (>80% annexin V positive; not depicted) were labeled with the fluorescent dye DiD (Invitrogen). J774 Cells were washed and incubated with the fluorescent substrates for 30 min at 37degreesC (in PBS with 0.5% BSA), washed three times, and analyzed by flow cytometry. ELISA, flow cytometry, and RT-PCR were performed as described. Bone marrow-derived macrophages were generated from BALB/c mice as previously described (8).
###end p 66
###begin title 67
Autoantibody analysis.
###end title 67
###begin p 68
###xml 25 28 25 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib69">69</xref>
###xml 487 489 487 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib44">44</xref>
###xml 50 54 <span type="species:ncbi:10090">mice</span>
Serum ANAs in BALB/c.TLR7-/- and wild-type BALB/c mice were determined 12 and 24 wk after TMPD by indirect immunofluorescence using HEp-2 cells (Innova). Sera were diluted 1:40, and titers were determined using a titration emulation system (Image Titer; Rhigene, Inc.). Immunoprecipitation and antigen-capture ELISA to detect serum autoantibodies against nRNP/Sm were performed as previously described (26, 69). Determination of anti-Su/ago2 by ELISA has also been previously described (44). Recombinant ago2 protein was a gift from E. Chan and K. Ikeda (University of Florida, Gainesville, FL).
###end p 68
###begin title 69
Statistical analysis.
###end title 69
###begin p 70
###xml 95 96 95 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
For quantitative variables, differences between groups were analyzed by the unpaired Student's t test. Survival curves were analyzed using the log-rank test. ANA titers and autoantibody levels were compared using the Mann-Whitney U test. Data are presented as means +/- SD. All tests were two-sided, and P < 0.05 was considered significant. Statistical analyses were performed using Prism 4.0 software (GraphPad Software, Inc.).
###end p 70
###begin title 71
Online supplemental material.
###end title 71
###begin p 72
###xml 101 104 101 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 239 242 239 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 105 109 <span type="species:ncbi:10090">mice</span>
###xml 243 247 <span type="species:ncbi:10090">mice</span>
Table S1 provides PCR array analysis of cytokine/chemokine expression in PECs from wild-type and TLR7-/- mice. Table S2 provides the sequence of all PCR primers used in this study. Fig. S1 shows the levels of proteinuria in BALB/c and TLR7-/- mice 24 wk after TMPD treatment. Fig. S2 shows the effect of TMPD on endocytosis of FITC-dextran and phagocytosis of FITC-coated latex beads or apoptotic lymphocytes in J774 cells. Online supplemental material is available at .
###end p 72
###begin title 73
Supplementary Material
###end title 73
###begin title 74
[Supplemental Material Index]
###end title 74
###begin p 75
We thank Dr. E. Sobel for helpful discussion, M. Xu for assistance with manuscript preparation, Drs. E. Chan and K. Ikeda for providing recombinant ago2 protein, and Dr. N.S. Szabo for gas chromatography/mass spectroscopy analysis of hydrocarbon oil mixed with FCS. The work was supported with resources and the use of facilities at the Malcolm Randall Veterans Administration Medical Center.
###end p 75
###begin p 76
This work was supported by research grants AR44731, AR51766, and AR050661 from the United States Public Health Service, and by generous gifts from Lupus Link, Inc. and Mr. L.M. Schott to the University of Florida Center for Autoimmune Disease. P.Y. Lee and J.S. Weinstein are National Institutes of Health T32 trainees (DK07518 and AR007603). D.C. Nacionales is the recipient of an Arthritis Foundation Postdoctoral Fellowship.
###end p 76
###begin p 77
The authors have no conflicting financial interests.
###end p 77

